Mayo Clinic
Rochester, Minnesota, 55905, United States
NCT Number: NCT02016235
Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.
Looking for future studies?
Notify MeMale
Interventional
Phase 1 / Phase 2
Rochester, Minnesota, 55905, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients will be recruited from those in the RKSC Dent Registry
Exclusion criteria
250 mg po qid
Other names: K-phos neutral
Baseline blood and urine measurements only
Time frame: baseline, day 7
Urine protein tests detect and/or measure protein being released into the urine. Normal urine protein elimination is less than 150 mg/day
Mayo Clinic
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04459013
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dent Disease
Paris, Île-de-France Region, France
View Trial DetailsNCT02124395
Adenine Phosphoribosyl Transferase Deficiency, Adenine phosphoribosyltransferase deficiency
Rochester, Minnesota, United States
View Trial DetailsNCT01783795
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dent Disease
Rochester, Minnesota, United States
View Trial DetailsNCT02022189
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dent Disease
Rochester, Minnesota, United States
View Trial Details